Medicare drug price negotiations need something new: a floor
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.
Medicare’s Selection Of 15 More Drugs For Price Negotiation Puts Spotlight Back On IRA
The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
Medicare to negotiate prices for top drugs
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.
Medicare targets 15 more drugs for price negotiations -- including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Ozempic among drugs selected for Medicare price negotiations as Biden exits
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.
Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy
The Centers for Medicare and Medicaid Services' (CMS) announcement of 15 new drugs to be subject to price controls under the Inflation Reduction Act (IRA) represents the continuation of a flawed federal policy that has failed to achieve its stated goals and is causing significant health and economic harm.
Biden Adds Ozempic to Medicare Price Renegotiation Talks
Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.
Trump rolls back effort to lower Medicare, Medicaid drug costs
Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.
Becker's Hospital Review5d
Why not tie Medicare payments to inflation?
Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.
Capital Public Radio1d
Prescription costs are going way down for millions as part of Inflation Reduction Act
In 2025, more than 3 million seniors are going to save thousands of dollars because of a new spending limit on prescription drugs. It's unclear whether the Trump Administration will keep the law.
Trump's reversal on medicine cap cut could impact senior citizens, but benefits economy
An economy expert says short term, senior citizens will continue to carry the high costs of prescription drugs. but President ...
Becker's Hospital Review19h
Health systems brace for more Medicare, uncompensated care
Hospitals are also seeing higher uncompensated care as individuals lose Medicaid coverage or decide not to purchase health insurance. If there are changes to the health insurance exchanges, more ...
Tom Zirpoli: Promises made, promises broken | COMMENTARY
Even before he took his oath of office on Monday, Donald Trump and his transition team were backing away from his campaign ...
Health Care Roundup: Market Talk
Find insight on Novartis, GSK and more in the latest Market Talks covering Health Care.
JD Supra19h
Drug Pricing and Health Care Fraud Remain Key Issues
Key Points - - It remains to be seen what priorities Robert F. Kennedy Jr. and Marty Makary might set if confirmed as HHS secretary ...